Sana Biotechnology logo

Sana BiotechnologyNASDAQ: SANA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 February 2021

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$569.34 M
-85%vs. 3y high
68%vs. sector
-vs. 3y high
-vs. sector
-77%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:18:13 GMT
$2.55$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

SANA Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Sana Biotechnology, Inc. (SANA) Regarding Possible Securities Fraud Violations
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Sana Biotechnology: The Story Becomes Murkier
seekingalpha.com19 November 2024 Sentiment: NEGATIVE

Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future.

Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANA
accesswire.com19 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
accesswire.com16 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– SANA
accesswire.com14 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher
zacks.com13 November 2024 Sentiment: POSITIVE

Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
accesswire.com12 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SANA
accesswire.com12 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
zacks.com11 November 2024 Sentiment: POSITIVE

Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  • 1(current)

What type of business is Sana Biotechnology?

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

What sector is Sana Biotechnology in?

Sana Biotechnology is in the Healthcare sector

What industry is Sana Biotechnology in?

Sana Biotechnology is in the Biotechnology industry

What country is Sana Biotechnology from?

Sana Biotechnology is headquartered in United States

When did Sana Biotechnology go public?

Sana Biotechnology initial public offering (IPO) was on 04 February 2021

What is Sana Biotechnology website?

https://www.sana.com

Is Sana Biotechnology in the S&P 500?

No, Sana Biotechnology is not included in the S&P 500 index

Is Sana Biotechnology in the NASDAQ 100?

No, Sana Biotechnology is not included in the NASDAQ 100 index

Is Sana Biotechnology in the Dow Jones?

No, Sana Biotechnology is not included in the Dow Jones index

When was Sana Biotechnology the previous earnings report?

No data

When does Sana Biotechnology earnings report?

The next expected earnings date for Sana Biotechnology is 28 February 2025